Fig 2: Progression-free survival (PFS) according to RRM1 (a) and ERCC1 (b) expression, high vs low. Overall survival (OS) according to RRM1 (c) and ERCC1 (d) expression, high vs low

Fig 3: Immunohistochemical staining of XRCC1, ERCC1 and ERCC2 expression in OSCC tissues. ERCC1, ERCC2 or XRCC1 expression in oral normal tissues and cancer tissues, determined by immunohistochemistry, was divided into 4 categories according to the staining intensity: Score 0, no staining; score 1, weak staining; score 2, moderate staining; and score 3, strong staining. Original magnification, ×200. XRCC1, X-ray repair cross-complementing group 1; ERCC1/2, excision repair cross-complementing group 1/2; OSCC, oral squamous cell carcinoma.

Fig 4: Disease-free survival and overall survival rates of patients with oral squamous cell carcinoma divided in low and high XRCC1, ERCC1 and ERCC2 expression groups. Survival curves were generated using the Kaplan-Meier method and the P-values were calculated using the log-rank test. XRCC1, X-ray repair cross-complementing group 1; ERCC1/2, excision repair cross-complementing group 1/2.

Fig 5: Immunohistochemical analysis for ERCC1, RRM1, RRM2, and hENT-1 expression in malignant pleural mesothelioma patients. High and low nuclear expression for ERCC1 (a, b), and high and low cytoplasmic expression for RRM1 (d, e), RRM2 (g, h), and hENT-1 (j, k), respectively. Negative controls (without primary antibody) are shown for each molecule in c, f, i, and l, respectively